Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 36

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Recruiting

Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Immune thrombocytopenia

Recruiting

Study Comparing Avatrombopag and Rituximab for Adults with Immune Thrombocytopenia Not Responding to Corticosteroids

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Avatrombopag
  • Sponsor:Ostfold Hospital Trust

Myasthenia gravis

Recruiting

Study on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Myocarditis+2

Recruiting

Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Antwerp University Hospital

Psoriatic arthropathy

Recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic scleroderma+1

Recruiting

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Interstitial lung disease

Recruiting

Study on the Effects of Morphine Sulfate for Relieving Breathlessness and Cough in Patients with Fibrotic Interstitial Lung Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Morphine Sulfate
  • Sponsor:Region Midtjylland

Rheumatoid arthritis

Recruiting

Study on the Safety and Effectiveness of Abatacept and Daratumumab for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Colitis ulcerative

Recruiting

Study on the Effectiveness of Ozanimod for Children with Moderate to Severe Ulcerative Colitis Not Responding to Usual Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Juvenile psoriatic arthritis

Recruiting

Study on the Effects of Risankizumab and Adalimumab in Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute graft versus host disease+1

Recruiting

Study Comparing Methylprednisolone and Methoxsalen for Treating Grade II Acute Graft-Versus-Host Disease in Adult Stem Cell Transplant Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Methoxsalen
  • Sponsor:CHRU De Nancy

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.